[go: up one dir, main page]

MA33323B1 - Thérapie adjuvante de cancer - Google Patents

Thérapie adjuvante de cancer

Info

Publication number
MA33323B1
MA33323B1 MA34342A MA34342A MA33323B1 MA 33323 B1 MA33323 B1 MA 33323B1 MA 34342 A MA34342 A MA 34342A MA 34342 A MA34342 A MA 34342A MA 33323 B1 MA33323 B1 MA 33323B1
Authority
MA
Morocco
Prior art keywords
cancer
adjuvant therapy
adjuvant
compositions
provides methods
Prior art date
Application number
MA34342A
Other languages
Arabic (ar)
English (en)
Inventor
Gwendolyn Fyfe
Eric Hedrick
Robert D Mass
Norman Wolmark
Original Assignee
Genentech Inc
Nsabp Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Nsabp Foundation Inc filed Critical Genentech Inc
Publication of MA33323B1 publication Critical patent/MA33323B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fertilizers (AREA)

Abstract

La présente invention porte sur des procédés et des compositions comprenant des anticorps anti-VEGF pour une utilisation dans une thérapie adjuvante de cancer.
MA34342A 2009-04-20 2010-04-20 Thérapie adjuvante de cancer MA33323B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17100809P 2009-04-20 2009-04-20
US17131809P 2009-04-21 2009-04-21
US18119509P 2009-05-26 2009-05-26
PCT/US2010/031740 WO2010123891A1 (fr) 2009-04-20 2010-04-20 Thérapie adjuvante de cancer

Publications (1)

Publication Number Publication Date
MA33323B1 true MA33323B1 (fr) 2012-06-01

Family

ID=42235124

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34342A MA33323B1 (fr) 2009-04-20 2010-04-20 Thérapie adjuvante de cancer

Country Status (19)

Country Link
US (1) US20100266589A1 (fr)
EP (1) EP2421558A1 (fr)
JP (1) JP2012524083A (fr)
KR (1) KR20120096401A (fr)
CN (1) CN102458467A (fr)
AR (1) AR076344A1 (fr)
AU (1) AU2010239368A1 (fr)
BR (1) BRPI1006438A2 (fr)
CA (1) CA2759030A1 (fr)
CL (1) CL2011002610A1 (fr)
CO (1) CO6450651A2 (fr)
CR (1) CR20110553A (fr)
IL (1) IL215764A0 (fr)
MA (1) MA33323B1 (fr)
MX (1) MX2011010955A (fr)
RU (1) RU2011147051A (fr)
SG (1) SG175289A1 (fr)
TW (1) TW201106969A (fr)
WO (1) WO2010123891A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02371B (fr) * 2006-09-29 2016-06-20 Oncomed Pharm Inc Compositions et procédés permettant de diagnostiquer et de traiter le cancer
EP3485908B1 (fr) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Combinaison thérapeutique et utilisation d'anticorps antagonistes de dll4 et d'agents anti-hypertenseurs
EP4190149A1 (fr) 2009-12-25 2023-06-07 Chugai Seiyaku Kabushiki Kaisha Procédé de recherche et de criblage de cible d'agent anticancéreux à l'aide d'un modèle animal non humain ayant une lignée cellulaire cancéreuse établie nog transplantée
CA3240281A1 (fr) 2010-06-03 2011-12-08 Pharmacyclics Llc Utilisation d'inhibiteurs de la tyrosine-kinase de bruton dans le traitement du lymphome folliculaire
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US11124773B2 (en) 2010-10-06 2021-09-21 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell population and method for production thereof
WO2013035824A1 (fr) 2011-09-07 2013-03-14 ファーマロジカルズ・リサーチ プライベート リミテッド Séparation de cellules souches cancéreuses
MY188192A (en) 2011-09-23 2021-11-24 Oncomed Pharm Inc Vegf/dll4 binding agents and uses thereof
EP2772268B8 (fr) 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Molécule spécifique des cellules souches cancéreuses
WO2013181452A1 (fr) * 2012-05-31 2013-12-05 Genentech, Inc. Procédés de traitement du cancer au moyen d'antagonistes liant l'axe pd-1 et d'antagonistes de vegf
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
JP6464085B2 (ja) * 2012-08-07 2019-02-06 ジェネンテック， インコーポレイテッド 神経膠芽腫の治療のための併用療法
WO2014071018A1 (fr) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Méthodes et surveillance d'un traitement par un antagoniste de dll4
CA2890111A1 (fr) 2012-11-02 2014-05-08 Pharmacyclics, Inc. Therapie adjuvante par inhibiteur de kinase de la famille tec
US20140348821A1 (en) * 2013-05-24 2014-11-27 Nsabp Foundation, Inc. Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
CA2942528A1 (fr) 2014-03-20 2015-09-24 Pharmacyclics Inc. Mutations de phospholipase c gamma 2 et associees aux resistances
JP2017523776A (ja) 2014-07-14 2017-08-24 ジェネンテック， インコーポレイテッド 膠芽腫の診断方法及びその治療用組成物
MX382902B (es) 2014-10-31 2025-03-13 Oncomed Pharm Inc Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
WO2017042318A1 (fr) * 2015-09-10 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptide de chémérine pour le traitement de la cachexie provoquée par le cancer
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (fr) * 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
CN100480269C (zh) * 1997-04-07 2009-04-22 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US20050186208A1 (en) * 2003-05-30 2005-08-25 Genentech, Inc. Treatment with anti-VEGF antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20060009360A1 (en) * 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
EP3095455A1 (fr) * 2006-12-19 2016-11-23 Genentech, Inc. Antagonistes spécifiques de vegf pour thérapie par adjuvant et néoadjuvant et traitement de tumeurs à un stade précoce
ZA200904860B (en) * 2007-02-01 2010-09-29 Genentech Inc Combination therapy with angiogenesis inhibitors
AR069501A1 (es) * 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)

Also Published As

Publication number Publication date
CL2011002610A1 (es) 2012-04-09
WO2010123891A1 (fr) 2010-10-28
AR076344A1 (es) 2011-06-01
AU2010239368A1 (en) 2011-11-10
JP2012524083A (ja) 2012-10-11
CN102458467A (zh) 2012-05-16
MX2011010955A (es) 2012-04-02
RU2011147051A (ru) 2013-05-27
CR20110553A (es) 2012-01-23
SG175289A1 (en) 2011-11-28
KR20120096401A (ko) 2012-08-30
EP2421558A1 (fr) 2012-02-29
TW201106969A (en) 2011-03-01
IL215764A0 (en) 2012-01-31
CO6450651A2 (es) 2012-05-31
BRPI1006438A2 (pt) 2016-09-27
CA2759030A1 (fr) 2010-10-28
US20100266589A1 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
MA33323B1 (fr) Thérapie adjuvante de cancer
MA32535B1 (fr) Compositions et procédés pour des anticorps ciblant une protéine du complément c5
MA32126B1 (fr) Anticorps et immunoconjugués anti-cd79b et leurs procédés d'utilisation
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
PH12013501339A1 (en) Anti-pcsk9 antibodies and methods of use
MY166776A (en) Humanised anti-ctla4 antibodies
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
ME03608B (fr) Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer
MA34524B1 (fr) Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3)
EA201171367A1 (ru) Винилиндазолильные соединения
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
MX2010005080A (es) Metodos y composiciones para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40.
MX2012014080A (es) Usos y composiciones para el tratamiento de hidradenitis superativa (hs).
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
UA99339C2 (ru) Антитело, которое специфично связывает человеческий tyrp1
MX340555B (es) Anticuerpos contra il-18r1 y usos de los mismos.
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
GB0515353D0 (en) Food
MX336323B (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
PH12013500616A1 (en) Antibody compositions and methods of use
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use